CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
neoadjuvant
A collection of 47 issues
Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response
Skip to content
The CRC Digest
Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response
A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res)
This content is informational only
CRC Research Update — September 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer
This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon
CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights
Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer
The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology)
This content is informational
Dual immunotherapy shows promise in mismatch repair proficient colon cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy shows promise in mismatch repair proficient colon cancer
The phase 2 NEST trial tested neoadjuvant botensilimab plus balstilimab in patients with resectable colon cancer. The study examined safety, feasibility, and pathologic response before surgical resection. (Clinical Cancer Research)
This content
CRC Research Update — August 26, 2026
Today's colorectal cancer research highlights